Skip to main content
. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047

Table 1.

Summary of demographic and baseline clinical characteristics of patients with MS treated with natalizumab included in the study

graphic file with name NEURIMMINFL2014002105TT1.jpg